<DOC>
	<DOCNO>NCT01375998</DOCNO>
	<brief_summary>This study regulatory post marketing surveillance Japan , local prospective observational study patient receive YAZ dysmenorrhea . The objective study ass safety efficacy use YAZ clinical practice . A total 3,000 patient recruit follow 3 year since start YAZ administration .</brief_summary>
	<brief_title>YAZ Post-marketing Surveillance Japan</brief_title>
	<detailed_description />
	<mesh_term>Dysmenorrhea</mesh_term>
	<criteria>Patients receive YAZ dysmenorrhea Additional criterion QOL questionnaire Patient inform consent Patients contraindicate base product label Additional criterion QOL questionnaire Six month less treatment estrogen estrogen combination drug</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>YAZ</keyword>
	<keyword>Dysmenorrhea</keyword>
</DOC>